About Hemosphere (formerly GRAFTcath)
Hemosphere (formerly GRAFTcath) has developed a vascular access product that has the potential to reduce the risk of bacteremia, or severe infection, posed to catheter-dependent patients undergoing hemodialysis.
Missing: Hemosphere (formerly GRAFTcath)'s Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Hemosphere (formerly GRAFTcath)'s Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Hemosphere (formerly GRAFTcath) Frequently Asked Questions (FAQ)
Where is Hemosphere (formerly GRAFTcath)'s headquarters?
Hemosphere (formerly GRAFTcath)'s headquarters is located at 6545 City West Parkway, Eden Prairie.
Who are Hemosphere (formerly GRAFTcath)'s competitors?
Competitors of Hemosphere (formerly GRAFTcath) include MedShape, Respicardia, Access Scientific, TherOx, arstasis and 12 more.
Compare Hemosphere (formerly GRAFTcath) to Competitors
GRAFTcath is a medical device company developing vascular access products for hemodialysis.
Claros Diagnostics is an early stage device company developing a POC multiplex diagnostic focused on a biomarker panel for prostate cancer.
Primaeva Medical is an early stage medical device company developing a skin tightening and rejuvenation dermatological device
ExploraMed is a medical technology incubation company dedicated to the identification, creation and development of medical device solutions. ExploraMed creates ideas in the fields of clinical, engineering, legal, strategic marketing, and financing, while focusing on efficient and timely development.
UroCor Labs aims to provide a menu of diagnostic services to assist in detecting, diagnosing, treating and managing prostate cancer, bladder cancer, kidney stones, and other complex urologic disorders.
a medical device company, based in part on intellectual property of CardioVascular Technologies, Inc. (http://cvtechinc.com), and is focused on the development and commercialization of the vascular access closure technology for the Interventional Cardiology market. The company is comprised of several seasoned medical device professionals and physicians, with a proven record of innovation, clinical acumen, access to the industry and successful commercialization of multiple medical device technologies.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.